- Pegylated-interferon-lambda is a potent antiviral cytokine that acts to generate an antiviral state within cells
- Potential to stem viral shedding to mitigate transmission and prevent disease progression once administered
- Demonstrated potent antiviral effects against various viruses including coronaviruses in cell and animal models
- First trials of Peginterferon Lambda started in April
- Subsequent trials started rolling out this month, on what can be assumed as early signs of positive data
“The therapeutic toolbox for covid19 continues to expand, not only with treatments that can prevent virus from replicating and infecting its host; but also therapies that may help people after they get sick. Here the growing case for peginterferon lambda-1a”Scott Gottlieb, MD – 23rd Commissioner of the FDA via Twitter
“The researchers chose interferon-lambda because it acts on fewer body tissues than interferon-alfa does. That could translate into fewer side effects.
We don’t have a vaccine yet, Treating mild to moderate disease is an important area to focus on.”Dr. Upinder Singh – Stanford University via HealthDay.com
University of Toronto
“Our PegIFN-l treatment trial is addressing two key components of COVID-19: preventing severe disease and getting healthy people to clear the virus quickly so they can get back to their lives.”Dr. Jordan Feld, Co-Director of the Schwartz Reisman Liver Research Centre via tgwhf.ca
Mass General Hospital
“We chose FN-lambda because of the strength of its preclinical data and the precedent for interferon’s clinical efficacy against other coronaviruses.
The finding published in Cell that in the early stages of human SARS-CoV-2 infection, there is a weak interferon response. “RAYMOND CHUNG, MD – Massachusetts General Hospital via massgeneral.org
Soroka University, Israel
In comments from a previous lambda HDV study, now expanded to cover COVID-19 “Fewer episodes of cytopenia, flu-like symptoms, and psychiatric events in this study make Lambda interferon particularly attractive for further development as a monotherapy”Ohad Etzion, MD, Director – Soroka University Medical Center
Johns Hopkins University
Mark Sulkowski is running the Peginterferon Lambda-1a trials at Johns Hopkins University that started in April.
Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 Infection via clinicaltrials.govMark Sulkowski, MD – Johns Hopkins University
Mount Sinai Hospital
Thomas Marron will run the Interferon Lambda trials at Mount Sinai Hospital, expected to start this month.
Interferon Lambda Therapy for SARS-CoV-2 Infection via clinicaltrials.govThomas Marron, MD – Icahn School of Medicine at Mount Sinai